

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB04/005365

International filing date: 20 December 2004 (20.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0329449.3
Filing date: 19 December 2003 (19.12.2003)

Date of receipt at the International Bureau: 24 January 2005 (24.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



PCT/GB 2004 / 0 0 5 3 6 5



INVESTOR IN PEOPLE


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Stephen Hordley

Dated 18 January 2005




The
Patent
Office

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office
Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference	59.82765		
2. Patent application number (The Patent Office will fill in this part)	0329449.3		19 DEC 2003
3. Full name, address and postcode of the or of each applicant (<u>underline all surnames</u>)	OmniCyte Ltd 21 Wilson Street London EC2M 2TD Patents ADP number (if you know it) 8776023001 If the applicant is a corporate body, give country/state of its incorporation United Kingdom		
4. Title of the invention	Stem Cells		
5. Name of your agent (if you have one)	Frank B. Dehn & Co.		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	179 Queen Victoria Street London EC4V 4EL Patents ADP number (if you know it) 166001		
6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)	Number of earlier UK application	Date of filing (day / month / year)	
8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request? Answer YES if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. Otherwise answer NO (See note d)	Yes		

Patents Form 1/77

9. ~~Accompanying documents:~~ A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form

Description 17

Claim(s)

Abstract

Drawing(s) 12 + 2 *ll*

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for a preliminary examination and search (*Patents Form 9/77*)

Request for a substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application.
Frank B Delmuc
Signature Date 19 December 2003

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

Rebecca Gardner
01273 244200

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
b) Write your answers in capital letters using black ink or you may type them.
c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s) of the form. Any continuation sheet should be attached to this form.
d) If you have answered 'Yes', Patents Form 7/77 will need to be filed.
e) Once you have filled in the form you must remember to sign and date it.
f) Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7, you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

82765.209

Stem Cells

5 The present invention relates to stem cells, in particular to a new type of adult stem cells isolatable from bone marrow and blood.

 Stem cells can produce new cells to repair damage to any tissue in the body and therefore have immense
10 potential for all types of regenerative medicine. Stem cells are present in all body tissues and organs but some, like bone marrow and blood, are more accessible than others, like liver and brain. However, stem cells exist in very small numbers in marrow and blood, and need
15 to be extracted then increased in number ("expanded") before they can be used clinically. Currently, many attempts are being made to accomplish the aim of providing stem cells in sufficient numbers to perform tissue-specific stem cell transplantation.

20 Efforts have focussed on the bone marrow as a source of stem cells. Evidence to date suggest that the bone marrow contains two types of stem cells - haemopoietic stem cells (HSC) responsible for producing blood, and mesenchymal stem cells (MSC) capable of producing cells
25 belonging to a limited range of body tissues. MSC can not be precisely defined or isolated and show a limited capacity to provide multiple cell types. They form osteoblasts, chondroblasts and adipocytes in response to stimulation in culture but there are many cell types,
30 such as hepatocytes, which they cannot form. Prolonged culture of MSC results in the outgrowth of a subpopulation of cells referred to as multipotent adult progenitor cells (MAPC) which to date appear to have the broadest potential for tissue regeneration. However, the
35 fact the prolonged tissue culture and many cell divisions are required before MAPC emerge, means first that they

may have accumulated genetic damage and second, that it is impossible to be certain that they represent normal cellular components of the bone marrow. They may, in fact, be a tissue culture artefact. These important
5 considerations potentially contra-indicate the clinical use of MAPC. MAPC can form cells with endodermal, ectodermal or mesodermal markers but, significantly, do not produce haemopoietic cells in culture.

Using differentiated cells derived from stem cells
10 to produce their natural protein products has advantages over the use of cells to produce recombinant proteins, particularly because of the capability for appropriate glycosylation and post-translational modification of the protein product.

15 The present inventors have now identified a new type of pluripotent stem cell which can be directly isolated from bone marrow and blood e.g. peripheral or taken from the umbilical cord and have the unique ability to differentiate into ectodermal, mesodermal and endodermal
20 cells. These cells are thus clearly multipotent if not totipotent. Thus the adult, i.e. non-foetal, stem cells described herein provide a novel source of cells for tissue transplantation that may be used in an autologous (self-to-self) manner. Further, as is described below,
25 these stem cells do not require prolonged tissue culture.

Thus, in one aspect the present invention provides an isolated adult stem cell population wherein said stem cells are CD34⁺, capable of self regeneration and capable of differentiation into ectodermal, mesodermal and
30 endodermal cells.

These stem cells are further characterised by their ability to adhere to plastic (e.g. the plastic of standard tissue culture vessels) during culturing. Suitable vessels are those manufactured by Corning
35 Incorporated, New York, USA.

The stem cells of the invention may be further characterised by the fact that they do not require feeder layers, i.e. cells (typically inactivated by gamma irradiation which supply important metabolites without further growth or division of their own) which support the growth of the stem cells. Thus, preferably, a feeder layer is not used during culturing of the stem cells.

One primary characterising and particularly advantageous feature of these stem cells is their ability to differentiate into a very wide variety of different cell types including ectodermal, mesodermal and endodermal cells. Thus, these stem cells of the invention can differentiate into cell types which are developmentally derived from the three germ layers of the embryo; ectoderm, mesoderm and endoderm; for example haemopoietic and muscle cells which are derived from the mesoderm; nerve or epithelial cells from the ectoderm; and glandular epithelium or hepatocytes from the endoderm.

The cell population is 'isolated' in that it is substantially free of other cell types, in particular of cells which express CD33, CD38, HLA/DR, CD19 and CD3. Also, the population is substantially free of cells dedicated to a particular lineage and/or cells carrying markers associated therewith. Preferably the population has less than 20%, more preferably less than 10%, e.g. less than 5% of lineage committed cells. It may assist in the isolation of the present stem cell population to combine both negative selection (removal of cells) and positive selection (isolation of cells), in both cases antibody binding may be used.

Stem cells are thought to be manufactured in the adult bone marrow but are also found in the blood. The present stem cells may be collected from either of these sources according to standard sampling techniques. Blood samples are preferably obtained following stem cell mobilisation with G-CSF to increase the numbers of stem

cells in the circulation. For example, 5 µg/kg body weight/day may be administered subcutaneously for 5 days. It is also possible to obtain direct bone marrow samples, e.g. through aspiration.

5 Bone marrow cells may be obtained from a source of bone marrow, e.g., iliac crests, tibiae, femora, spine, or other bone cavities. Conveniently bone marrow may be aspirated from the bone in accordance with conventional techniques. Other sources of the stem cells include
10 blood, including adult peripheral blood and umbilical cord blood.

Various techniques may be employed to separate the cells by initially removing cells of dedicated lineage. Monoclonal antibodies are particularly useful for
15 identifying markers (surface membrane proteins) associated with particular cell lineages and/or stages of differentiation. The antibodies may be attached to a solid support to allow for crude separation. The separation techniques employed should maximize the
20 retention of viability of the fraction to be collected. For "relatively crude" separations, that is, separations where up to 10%, usually not more than about 5%, preferably not more than about 1%, of the total cells present having the marker, may remain with the cell
25 population to be retained, various techniques of different efficacy may be employed. The particular technique employed will depend upon efficiency of separation, cytotoxicity of the methodology, ease and speed of performance, and necessity for sophisticated
30 equipment and/or technical skill.

Procedures for separation may include magnetic separation, using antibody-coated magnetic beads, affinity chromatography, cytotoxic agents joined to a monoclonal antibody or used in conjunction with a
35 monoclonal antibody, e.g., complement and cytotoxins, and "panning" with antibody attached to a solid matrix, e.g.,

plate, or other convenient technique. Techniques providing accurate separation include fluorescence activated cell sorters, which can have varying degrees of sophistication, e.g., a plurality of color channels, low
5 angle and obtuse light scattering detecting channels, impedance channels, etc.

Conveniently, the antibodies may be conjugated with markers, such as magnetic beads, which allow for direct separation, biotin, which can be removed with avidin or
10 streptavidin bound to a support, fluorochromes, which can be used with a fluorescence activated cell sorter, or the like, to allow for ease of separation of the particular cell type. Any technique may be employed which is not unduly detrimental to the viability of the remaining
15 cells.

Preferably the mononuclear fraction of the blood or bone marrow sample is separated using a Lymphoprep™ (Axis Shield) density gradient. CD34⁺ cells can be separated from the mononuclear fraction using MiniMACS (Miltenyi
20 Biotec) technology.

The stem cells of the present invention can be further characterised by the methods used to obtain them, thus the cells are obtainable by a combined affinity purification and selection by adherence method. More
25 particularly, the cells can be labelled with CD34 monoclonal antibody (MAb) and then with (para)magnetic beads which themselves bind to the CD34 MAb. Alternatively, beads which are themselves labelled with the CD34 MAb may be used which bind to the cells. The
30 labelled or bound cells can then be applied to a column and held in place by a magnet; unlabelled cells will be eluted and labelled cells released by removing the magnet (or by removing the column from the magnet).

The thus released CD34⁺ cells can then be incubated
35 in tissue culture plastic vessels for at least 2 hours, preferably at least 3 hours e.g. 3-5 hours, with

non-adherent cells removed by washing with HBSS (Hanks balanced salt solution). The adherent CD34⁺ cell population are the stem cells of the present invention and comprise less than 1% of the total CD34⁺ population.

5 They are preferably a substantially homogenous population, generally uncontaminated by other stem cell subpopulations. Typically less than 5%, preferably less than 3% of the cells collected are other than the stem cells of the present invention. 'Adherent' cells are
10 defined as those which are able to resist vigorous washing three times without detaching. The advantageous properties of the adherent subset of CD34⁺ cells are surprising as the adherent cells would usually be discarded when culturing cells.

15 The stem cells of the invention are capable of self-regeneration, i.e., in accordance with standard definitions of stem cells, each stem cell is capable of ~~division to form further stem cells, as well as~~
differentiation to a wide variety of different cell
20 types.

The stem cells of the invention are further characterised as CD34⁺, i.e. expressing the antigen CD34, a glycoprotein marker found, but not exclusively so, on stem cells, in particular the stem cells manufactured in
25 the bone marrow (HSC and MSC). The cells are also Thy-1⁺.

More particularly, the cells may be characterised as CD34⁺, Thy-1⁺, CD38⁻, CD33⁻ and HLA-DR⁻.

The stem cells are lymphocyte-like in that they are round mononuclear cells and rather small with a high
30 nucleus: cytoplasm ratio. Such a morphology is associated with primitive stem cells.

They are characterised by an ability to produce differentiated cells in less than 16, e.g. 12-14 days in culture. Preferably differentiation is observed in less
35 than 14 days, e.g. less than 10 days, more preferably in less than 7 days, even 4-5 days.

The stem cells of the invention can be further characterised as obtainable by:

- 5 (i) subjecting haemopoietic tissue (i.e. blood or a bone marrow sample) to density gradient separation;
- (ii) exposing low density cells to an affinity ligand for CD34 (preferably attached to paramagnetic beads);
- (iii) recovering cells attached to said CD34 ligand;
- 10 (iv) exposing the CD34⁺ subpopulation to tissue culture grade plastic; and
- (v) recovering CD34⁺ cells adherent to the plastic.

15 The stem cells of the invention may be from any animal, e.g. laboratory, livestock or companion animal; preferably primate and most preferably from humans.

In a further embodiment the present invention provides a culture comprising:

- 20 (i) an isolated adult stem cell population wherein said stem cells are CD34⁺, capable of self regeneration and capable of differentiation into ectodermal, mesodermal and endodermal cells; and
- (ii) a medium capable of supporting the growth of said
25 stem cells.

Once stem cells have been isolated, they may be propagated by growing in conditioned medium from stromal cells, such as stromal cells that can be obtained from
30 bone marrow, fetal thymus or fetal liver, and are shown to provide for the secretion of growth factors associated with stem cell maintenance, coculturing with such stromal cells, or in medium comprising maintenance factors supporting the proliferation of stem cells, where the
35 stromal cells may be autologous, allogeneic or xenogeneic. Before using in the coculture, the mixed

stromal cell preparations may be freed of haemopoietic cells employing appropriate monoclonal antibodies for removal of the undesired cells, e.g., with antibody-toxin conjugates, antibody and complement, etc. Alternatively,
5 cloned stromal cell lines may be used where the stromal lines may be allogeneic or xenogeneic. Thus, reference above to "medium" includes cells such as stromal cells.

In a further aspect, the invention provides a method of isolating an adult stem cell population wherein said
10 stem cells are CD34⁺, capable of self regeneration and capable of differentiation into ectodermal, mesodermal and endodermal cells, which method comprises taking a sample of blood or bone marrow from a subject and extracting said cell population therefrom. Preferred
15 extraction steps are discussed above and in the case of blood sampling there will typically be a first step of stem cell mobilisation which is preferably performed by administering G-CSF to the subject.

The stem cells of the present invention have utility
20 in research contexts, for example in detecting and evaluating growth factors relevant to stem-cell regeneration. The stem cells may also be of direct utility in the treatment of genetic diseases through gene modification or replacement in autologous stem cells. In
25 particular the cells may be used in the treatment of diseases associated with haemopoietic cells, such as β -thalassemia and sickle cell anemia, where a wild-type gene is introduced into the stem cells. Thus in a further aspect the invention provides an isolated adult
30 stem cell population wherein said stem cells are CD34⁺, capable of self regeneration and capable of differentiation into both haemopoietic and mesenchymal cells which further incorporate a therapeutic gene, for use in therapy. Equally, the invention provides a method
35 of gene therapy comprising administering to a patient in need thereof a population of stem cells wherein said stem

cells are CD34⁺, capable of self-regeneration and capable of differentiation into ectodermal, mesodermal and endodermal cells and incorporate a therapeutic gene. Suitable therapeutic genes will include a wild-type version of a gene which is defective in the patient or a drug resistance gene.

Without additional therapeutic genes the stem cells still have therapeutic utility, e.g. in regenerating the haematopoietic system of a patient deficient in stem cells.

Further utilities of great interest relate to the generation of different differentiated cell types from the stem cells of the invention. As shown in the Figures hereto, it has been possible to generate in advantageously short timescales mesenchymal, haemopoietic, endothelial, epithelial, tube-forming and dendrite-forming cells. The preparation of haemopoietic and mesenchymal cells being particularly preferred. Cells have been observed after 4-5 days with the appearance of liver, nerve, mesenchymal, endothelial, epithelial and haemopoietic cells.

The stem cells are cultured with a cocktail of different cytokines, depending on the desired cell type. The cocktail will typically comprise G-CSF, GM-CSF, IL-3 and stem cell factor, with HGF and FGF being added to stimulate differentiation of hepatocytes; nicotinamide and LY294002 to stimulate differentiation to pancreatic cells and FGF and dibutyryl cyclic AMP to encourage production of nerve cells. Other growth factors are known to the skilled man to be important in the differentiation of other cell types such as bone, cartilage, skeletal and cardiac muscle, kidney, lung, nerve, skin and endocrine tissue.

Thus, in a further aspect, the invention provides a method of producing a target cell type which comprises culturing the stem cells of the invention with a

plurality of growth factors. As described in the Examples and shown in the Figures, successful differentiation may be shown by visual inspection, flow cytometry or immunophenotyping. Cells expressing
5 albumin, α -fetoprotein, α -antitrypsin and hepatocyte growth factor receptor (HGF receptor) (properties of hepatocytes), vimentin (skeletal muscle and neuronal cells) and smooth muscle actin (muscle cells) have, for example, been confirmed.

10 The differentiated cells can then be transplanted into a patient in need thereof. Of particular benefit is the potential to generate differentiated cells for cell or tissue transplantation that are derived from the patient's own stem cells. Such techniques are known in
15 the art and use different routes of administration according to the particular target tissue. The liver for example is able to regenerate itself following introduction of a population of healthy liver cells, where the liver has been damaged, e.g. as a result of
20 Hepatitis infection or alcohol abuse. Immune suppression may be treated by administration of lymphocytes, muscle wasting by the introduction of skeletal muscle cells, diabetes through transplanting pancreatic cells and so on.

25 The cells may be administered in a localised manner, e.g. injected directly into a target organ such as the liver. Alternatively, the cells may be administered at a site remote from the target site, e.g. by intravenous delivery. Tissue targeting may be achieved by forming a
30 complex between the generated cell types and a targeting ligand, such as monoclonal antibodies, cell adhesion molecules and their ligands, cytokine, chemokine and toll-like receptors and their ligands. Such 'complexes' include cells which express the targeting ligand on their
35 cell surface.

In one preferred embodiment the transplanted cells are adapted to be tracked *in vivo*, i.e. they incorporate a labelling moiety which means the location of the cells in the body can be identified. Conveniently the cells
5 will incorporate iron compounds e.g. iron oxide, and then MRI can be used to confirm the location of the transplanted cells, in particular to confirm whether they have reached their target tissue. As described in Example 4, the MR agent Resovist® is a suitable iron
10 containing compound which can be taken up by the cells on incubation therewith.

Thus, according to further aspects, the invention provides differentiated cell populations prepared according to the method defined above and such cells for
15 use in therapy, as well as methods of medical treatment which comprise administration of these differentiated cell populations to a patient. In particular, the invention comprises a method for the transplantation of a population of differentiated cells, the method
20 comprising:

- (i) culturing a population of the stem cells of the present invention with a plurality of growth factors so as to cause differentiation thereof; and
- 25 (ii) transplanting said differentiated cells into a patient.

Preferably the patient is human and also preferably, the stem cells which are cultured to produce the differentiated cells are from the patient.

30 The short time required from taking a sample from a patient and growing up differentiated cells for administration is a particular benefit provided by the present invention.

The stem cells of the invention and differentiated
35 cells derived therefrom may also be used in the *in vitro* production of proteins of interest. Thus in a further

aspect the invention provides an *in vitro* method of protein production which comprises culturing the stem cells of the invention or a differentiated cell line derived therefrom and then harvesting the cells and
5 recovering one or more of the proteins expressed by said cells.

Animal cells have become the predominant protein expression system for *in vitro* production of target proteins, particularly therapeutic agents, because of
10 their ability to perform post-translational modification (e.g. glycosylation) of proteins. The stem cells of the invention and their differentiated progeny can be used in the production of most if not all proteins of therapeutic interest, such as EPO, growth factors, protein hormones
15 such as insulin etc. or synthetic proteins. The cells may be genetically modified in order to provide or enhance production of a particular target protein. However it is a particularly desirable feature of the cell types enabled by the present invention that
20 differentiation to an appropriate cell type (e.g. parenchymal cells) can be performed such that the cells naturally produce the target protein without the need for genetic engineering.

The above described uses of the cells of the
25 invention (stem and differentiated) are also applicable to non-protein products such as steroids, in both cases, suitable culturing and harvesting techniques are known to the skilled man.

The stem cells of the invention have the necessary
30 cellular machinery to propagate vectors such as adenovirus, retrovirus, adeno-associated virus etc.; this is an essential step for current good manufacturing practice (cGMP) preparation of such vectors. Thus, in a further aspect, the present invention provides the use of
35 the stem cells of the invention as defined and described herein in vector, particularly viral vector, production.

Alternatively viewed, the invention provides a method of vector production wherein the vector of interest is propagated in a stem cell of the invention as defined and described herein. The vector (a transmissible agent) is typically a viral vector such as an adenovirus, retrovirus or adeno-associated virus.

The invention will be further described in the following non-limiting Examples and with reference to the Figures in which:

Figures 1-10 are photographs showing the stem cells of the invention and their differentiation over time into mesenchymal cells (Fig. 3, 5 and 6), haemopoietic cells (Fig. 4), epithelioid cells (Figs. 7 and 8), tube-forming cells (Fig. 9) and dendrite-forming cells (Fig. 10).

Figure 11 is a photograph showing how CD34⁺ cells were able to take up Resovist® (Schering AG) according to the protocol described in Example 4. According to this figure the individual spots represent the following:

1. 10⁶ cells, 0.25 mmol Resovist, overnight incubation
2. 10⁶ cells, 0.25 mmol Resovist + beads, overnight incubation
3. 10⁶ cells, beads, overnight incubation
4. 10⁶ cells, negative control (no staining)
5. 5x10⁵ cells, negative control (no staining)
6. 5x10⁵ cells, 0.25 mmol Resovist, overnight incubation
7. 5x10⁵ cells, 0.25 mmol Resovist + beads, overnight incubation
8. 5x10⁵ cells, beads, overnight incubation
9. 10⁶ cells, 0.25 mmol Resovist, 2h incubation
10. 10⁶ cells, 0.25 mmol Resovist + beads, 2h incubation
11. 10⁶ cells, beads, 2h incubation
12. 5x10⁵ cells, 0.25 mmol Resovist, 2h incubation
13. 5x10⁵ cells, 0.25 mmol Resovist + beads, 2h incubation
14. 5x10⁵ cells, beads, 2h incubation

15. beads only, no cells.

Figure 12 are photographs showing the
differentiation of stem cells into liver cells, as
evidenced by the presence of the liver cell markers
5 albumin and alpha fetoprotein.

Examples

Example 1. Cell extraction

5 Haematopoietic cells were obtained from bone marrow
or mobilised blood from normal individuals for
transplantation purposes. The mononuclear fraction was
separated from the whole using a Lymphoprep™ density
10 fraction using MiniMACS technology. Cells were first
labelled with CD34 monoclonal antibody and then with
paramagnetic beads. Labelled cells were loaded onto a
column held on a magnet, unlabelled cells were eluted and
labelled cells released by removing the column from the
15 magnet. The CD34⁺ cells were incubated in tissue culture
plastic vessels for at least 2h. Non adherent cells were
removed by washing with HBSS.

Example 2. Cell culture

20 Cells (2×10^5 /ml) were incubated in Methylcellulose
medium containing serum, 100ng/ml granulocyte colony
stimulating factor (G-CSF), 5ng/ml interleukin-3 (IL-3)
20ng/ml stem cell factor (SCF) and 1ng/ml granulocyte
25 macrophage colony stimulation factor (GM-CSF). This
resulted in heterogeneous populations of cells, which
subsequently can be characterised. Selected individual
populations were then targeted for differentiation using
tailored cytokine cocktails.

30

Example 3. Flow cytometry and immunocytochemistry

Flow cytometry. The adherent population that had
developed in the cultures was removed by scraping the
35 dish. Cells were fixed in 4% paraformaldehyde and
permeabilised. Cells were labelled with monoclonal

antibodies conjugated with FITC and analysed using Becton Dickinson flow cytometer.

5 Immunocytochemistry. The adherent population that had developed in the cultures was removed by scraping the dish. Cells were cytospun onto glass slides and fixed by methanol. Cells were labelled with monoclonal antibodies and visualised using the APAAP (alkaline phosphatase anti-alkaline phosphatase) reaction.

10

Results of flow cytometry and immunocytochemistry are shown in Table 1 below.

Table 1.

15

Antigen	Flow cytometry	Immunocytochemistry
Albumin	9.2%*	Large cells +ve**
Alpha feto protein	12.3%	Large cells +ve
Alpha 1 antitripsin	20.1%	N/A
cMET (HGF receptor)	34.9%	+ve
Smooth muscle actin	61.2%	Large cells +ve
GFAP(astrocytes)	57.4%	- ve
cKIT	22.1%	- ve
Vimentin	6.3%	Large cells +ve
hTERT	20.1%	- ve

* Denotes % of positive cells in the population

** Denotes that the large cells in the population were positive and the small cells were negative.

20

Albumin; alpha feto protein, alpha 1 antitripsin and cMET (HGF receptor) are liver cell markers; GFAP (astrocytes) is a brain cell marker; and smooth muscle actin is a marker for mesenchyme cells.

25

Figure 12 shows cells exhibiting liver cell markers after culturing for 12 days.

5 Example 4. Incorporation of iron oxide into cells and
labelling cells with paramagnetic beads

CD34⁺ (10^6 and 5×10^5) cells were incubated with
0.25 mmol Resovist® (the brand name of Ferrixan,
carboxy-dextran coated iron oxide nanoparticles available
10 from Schering AG) for 2 and 24 hours at 37°C and analysed
by MRI. In both cases, positive signal was obtained by
MRI suggesting possible use of Resovist in detecting CD34⁺
cells *in vivo*. The results of Figure 11 indicate that
the particles can be taken up by the cells and therefore
15 used in tracking the CD34⁺ cells or their differentiated
progeny as they move around the body or locate in target
tissues.

The *in vitro* toxicity of Resovist was also tested by
Trypan blue exclusion assay and proved to be
20 non-significant (<4%).

The results of this experiment are shown in Fig. 11.



CULTURE INITIATION

Fig. 1



ADHERENT CELLS - DAY 3

Fig. 2



MESENCHYMAL CELLS - DAY 7

Fig. 3



HAEMOPOIETIC CELLS - DAY 7

Fig. 4



MESENCHYMAL CELLS - DAY 14

Fig. 5



MESENCHYMAL CELLS - DAY 14

Fig. 6



EPITHELIOID CELL - DAY 14




Fig. 7



EPITHELIOID CELL - DAY 14




Fig. 8



TUBE-FORMING CELL - DAY 14




Fig. 9



DENDRITE-FORMING CELL - DAY 14




Fig. 10



11/12




Fig. 11






Fig. 12

